Prader-Willi Syndrome (PWS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Prader-Willi Syndrome (PWS) Market Outlook

Thelansis's "Prader-Willi Syndrome (PWS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prader-Willi Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Prader-Willi Syndrome (PWS) Overview

Prader-Willi Syndrome (PWS) is a rare, complex, multisystem disorder driven by loss of expression of paternally inherited imprinted genes on chromosome 15q11.2-q13. This genetic defect most commonly arises from a paternal deletion or maternal uniparental disomy, leading to profound hypothalamic dysfunction-the central driver of the disease phenotype.

Clinically, PWS follows a well-defined biphasic trajectory. The neonatal phase is marked by severe central hypotonia, poor feeding, and failure to thrive. This transitions in early childhood to pathologic hyperphagia, characterized by impaired satiety signaling and relentless food-seeking behavior. Without strict intervention, this results in rapid-onset obesity and downstream metabolic complications, including Type 2 Diabetes and severe Obstructive Sleep Apnea.

Beyond metabolic burden, PWS presents with a broad neurobehavioral and endocrine spectrum, including mild-to-moderate intellectual disability, compulsive behaviors, emotional dysregulation, hypogonadism, and central growth hormone deficiency. Management remains highly resource-intensive and multidisciplinary. Early initiation of recombinant human growth hormone (rhGH) therapy is the cornerstone of care, demonstrating benefits in linear growth, body composition, and metabolic parameters. However, there are no approved therapies targeting hyperphagia, which remains the most critical unmet need. As a result, long-term disease control depends heavily on stringent environmental measures (e.g., food security restrictions) and continuous caregiver supervision.

Key Highlights:

• PWS is a rare, lifelong, multisystem disorder driven by hypothalamic dysfunction, with a stable but gradually increasing diagnosed patient population in the US.
• The US prevalent population is estimated to grow from 13.9K in 2025 to 14.8K by 2035, reflecting a modest growth trajectory (0.6-0.7% CAGR) driven by improved diagnosis and survival.
• The disease is characterized by severe hyperphagia and obesity-related complications, representing the most critical unmet need due to the absence of approved targeted therapies.
• Increasing clinical focus on appetite-regulating and hypothalamic pathway-targeted therapies is expected to significantly transform the future treatment landscape.

Market Overview:

• The US PWS market is projected to expand from $559M in 2025 to $3.96B by 2035, reflecting a strong double-digit CAGR, primarily driven by late-stage pipeline therapies targeting hyperphagia.
• Current market revenues are largely supported by recombinant human growth hormone (rhGH) therapy, which addresses growth and metabolic aspects but not hyperphagia.
• Future market expansion will be highly dependent on successful commercialization of therapies targeting appetite dysregulation and improving long-term disease outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Harmony Biosciences Management, Inc.
• ConSynance Therapeutics
• Soleno Therapeutics, Inc.
• Bright Minds Biosciences Pty Ltd
• Aardvark Therapeutics, Inc.
• Pfizer
• Rhythm Pharmaceuticals, Inc.